New preprint alert! First authors Naveen and Raquel identify anti-folates as a strategy to treat cancers with p16 loss

Congrats to co-first authors Drs. Naveen Kumar Tangudu and Raquel Buj on their new preprint. Using CRISPR screens and pharmacological approaches, they identified purine metabolism as a metabolic vulnerability of p16-low cancers. Read more here: https://www.biorxiv.org/content/10.1101/2023.07.15.549149v2